Core Points - Quantum BioPharma Ltd. has announced the expiration of 53,147 warrants, which were part of a previous financing completed on October 20, 2020, marking the end of the last tranche of warrants issued to hedge funds and investment funds [1] - The company has set October 27, 2025, as the record date for the distribution of contingent value rights (CVRs) to holders of its Class B Subordinate Voting Shares, as part of a plan to deliver litigation-linked CVRs to shareholders [2][3] - Each CVR will allow holders to receive a pro rata portion of a minimum of 10% and up to 50% of the net proceeds from the company's legal action against CIBC World Markets, RBC Dominion Securities, and others, which alleges stock price manipulation and seeks damages exceeding USD $700 million [3][4] - The potential payment from the CVRs is contingent upon the company receiving Qualifying Net Proceeds from the litigation, and no payments will be made unless such proceeds are received [4][5] - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, aimed at preventing and reversing myelin degradation in multiple sclerosis [6] - The company retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is involved in the sales of unbuzzd™, and has a royalty agreement that provides 7% of sales until total payments reach $250 million, after which the royalty rate drops to 3% [6]
Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend